Pay in 4 interest-free payments of $7.00 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
If fasting glucose is trending upward, if IGF-1 exceeds normal ranges, or if side effects are becoming unmanageable, this is the point to reassess the protocol
Injectable options with established authorisation: Semaglutide 2.4 mg (Wegovy) : A once-weekly GLP-1 receptor agonist injection authorised by the MHRA for chronic weight management
It makes the pituitary gland release growth hormone by copying natural GHRH
Contact the prescribing provider if you develop a new symptom, have difficulty following the regimen or believe the treatment is affecting you differently than expected
Common Side Effects: Nausea, vomiting, diarrhea, and constipation
US$ 28.85
US$ 25.05
US$ 26.87
